Description Statistical models of plasma immunovirological features validate SARS-CoV-2 vRNA as an early predictor of COVID-19 mortality. Despite advances in COVID-19 management, identifying patients evolving toward death remains challenging. To identify early predictors of mortality within 60 days of symptom onset (DSO), we performed immunovirological assessments on plasma from 279 individuals. On samples collected at DSO11 in a discovery cohort, high severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral RNA (vRNA), low receptor binding domain–specific immunoglobulin G and antibody-dependent cellular cytotoxicity, and elevated cytokines and tissue injury markers were strongly associated with mortality, including in patients on mechanical ventilation. A three-variable model of vRNA, with predefined adjustment by age and sex, robustly identified patients with fatal outcome (adjusted hazard ratio for log-transformed vRNA = 3.5). This model remained robust in independent validation and confirmation cohorts. Since plasma vRNA’s predictive accuracy was maintained at earlier time points, its quantitation can help us understand disease heterogeneity and identify patients who may benefit from new therapies.
【초록키워드】 COVID-19, SARS-CoV-2, coronavirus, Mortality, cytokine, outcome, heterogeneity, Cohort, Immunoglobulin, Accuracy, management, Patient, death, plasma, Viral RNA, predictor, assessment, disease, Therapies, antibody-dependent cellular cytotoxicity, marker, COVID-19 mortality, Receptor binding, tissue injury, Predictive, symptom onset, acute respiratory syndrome, adjusted hazard ratio, help, cohorts, vRNA, description, quantitation, feature, benefit, independent, robust, identify, performed, collected, remained, elevated, individuals, age and sex, log-transformed, on mechanical ventilation, 【제목키워드】 plasma, SARS-CoV-2 RNA, COVID-19 mortality,